Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
The summary for the Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed): This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
| Federal Grant Title: | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | PAR-21-123 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.853 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | February 20th, 2024 |
| Original Application Deadline: | February 20th, 2024 |
| Posted Date: | March 11th, 2021 |
| Creation Date: | March 11th, 2021 |
| Archive Date: | March 27th, 2024 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | January 21st, 2022 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-21-123.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
- • Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VC...
- • NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed...
- • Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 C...
- • The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed)
- • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44)
- • NINDS Institutional Center Core Grants to Support Neuroscience Research
- • Career Development Award to Promote Diversity in Neuroscience Research
- More Grants from the National Institutes of Health
- • HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (UM1 Clinical Tri...
- • HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)
- • HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)
- • HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Req...
- • Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional D...
